Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction?

[1]  M. Metra,et al.  Heart failure: an update from the last years and a look at the near future , 2022, ESC heart failure.

[2]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[3]  C. Linde,et al.  Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF) , 2022, European journal of heart failure.

[4]  A. Fiorentino,et al.  Use of Cardiac Contractility Modulation in an Older Patient with Non-Ischemic Dilated Cardiomyopathy: A Case Report , 2021, Clinics and practice.

[5]  Sanjiv J. Shah,et al.  The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial , 2021, Nature Medicine.

[6]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[7]  C. Bode,et al.  Device interaction between cardiac contractility modulation (CCM) and subcutaneous defibrillator (S‐ICD) , 2021, Cardiovascular Electrophysiology.

[8]  D. Burkhoff,et al.  Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system , 2021, European journal of heart failure.

[9]  D. Burkhoff,et al.  Cardiac contractility modulation for the treatment of moderate to severe HF , 2020, Expert review of medical devices.

[10]  G. Filippatos,et al.  Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function , 2020, ESC heart failure.

[11]  R. D. de Boer,et al.  Left ventricular dysfunction in heart failure with preserved ejection fraction-molecular mechanisms and impact on right ventricular function. , 2020, Cardiovascular diagnosis and therapy.

[12]  N. Ali,et al.  Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction , 2020, Heart Failure Reviews.

[13]  F. Giallauria,et al.  A comprehensive individual patient data meta‐analysis of the effects of cardiac contractility modulation on functional capacity and heart failure‐related quality of life , 2020, ESC heart failure.

[14]  P. Ponikowski,et al.  Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[15]  D. Burkhoff,et al.  Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System , 2020, Circulation. Heart failure.

[16]  A. Goette,et al.  Cardiac contractility modulation improves long‐term survival and hospitalizations in heart failure with reduced ejection fraction , 2019, European journal of heart failure.

[17]  W. Maskoun,et al.  Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2019, Cardiovascular therapeutics.

[18]  D. Tint,et al.  New Generation Cardiac Contractility Modulation Device—Filling the Gap in Heart Failure Treatment , 2019, Journal of clinical medicine.

[19]  D. Burkhoff,et al.  Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond , 2018, European journal of heart failure.

[20]  D. Burkhoff,et al.  A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. , 2018, JACC. Heart failure.

[21]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[22]  M. LeWinter,et al.  Relaxation and the Role of Calcium in Isolated Contracting Myocardium From Patients With Hypertensive Heart Disease and Heart Failure With Preserved Ejection Fraction , 2017, Circulation. Heart failure.

[23]  T. Lawo,et al.  Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration. , 2016, International journal of cardiology.

[24]  D. Burkhoff,et al.  Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study. , 2016, International journal of cardiology.

[25]  W. Linke,et al.  Cardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF. , 2016, International journal of cardiology.

[26]  M. Borggrefe,et al.  Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices. , 2015, Heart rhythm.

[27]  D. Burkhoff,et al.  Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients. , 2015, International journal of cardiology.

[28]  C. Lam,et al.  How do patients with heart failure with preserved ejection fraction die? , 2013, European journal of heart failure.

[29]  M. Zile,et al.  Effects of Exercise on Left Ventricular Systolic and Diastolic Properties in Patients With Heart Failure and a Preserved Ejection Fraction Versus Heart Failure and a Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[30]  J. Sanderson,et al.  Cardiac Contractility Modulation for Heart Failure: A Meta‐Analysis of Randomized Controlled Trials , 2012, Pacing and clinical electrophysiology : PACE.

[31]  D. Burkhoff,et al.  Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure , 2012, European journal of heart failure.

[32]  M. Cannell,et al.  Local control in cardiac E-C coupling. , 2012, Journal of molecular and cellular cardiology.

[33]  E. Nøhr,et al.  Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. , 2011, Heart rhythm.

[34]  M. Neuss,et al.  Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[35]  G. Ng,et al.  Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions , 2011, European journal of heart failure.

[36]  D. Burkhoff,et al.  A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. , 2011, American heart journal.

[37]  M. Lohse,et al.  Ca2+ cycling and new therapeutic approaches for heart failure. , 2010, Circulation.

[38]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[39]  D. Burkhoff,et al.  A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. , 2008, American heart journal.

[40]  D. Burkhoff,et al.  Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. , 2008, Journal of the American College of Cardiology.

[41]  G. Hindricks,et al.  Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. , 2008, European heart journal.

[42]  H. Sabbah,et al.  Effects of Chronic Therapy with Cardiac Contractility Modulation Electrical Signals on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure , 2007, Cardiology.

[43]  A. Wals.  Reviews , 2007 .

[44]  D. Burkhoff,et al.  Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[45]  G. Lamas,et al.  Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM , 2007, European journal of heart failure.

[46]  D. Burkhoff,et al.  Nonexcitatory, cardiac contractility modulation electrical impulses: Feasibility study for advanced heart failure in patients with normal QRS duration , 2006 .

[47]  D. Burkhoff,et al.  Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. , 2006, Heart rhythm.

[48]  D. Burkhoff,et al.  Cardiac contractility modulation by non‐excitatory currents: Studies in isolated cardiac muscle , 2006, European journal of heart failure.

[49]  G. Hindricks,et al.  Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. , 2005, Journal of the American College of Cardiology.

[50]  D. Burkhoff,et al.  Electric currents applied during refractory period enhance contractility and systolic calcium in the ferret heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[51]  D. Burkhoff,et al.  A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. , 2015, Journal of cardiac failure.